- Home
- WEC vs ONC Comparison
WEC vs ONC Comparison
Compare WEC & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WEC | ONC |
|---|---|---|
| Founded | 1896 | 2010 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.3B | 34.8B |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | WEC | ONC |
|---|---|---|
| Price | $114.14 | $362.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 12 |
| Target Price | $118.42 | ★ $370.25 |
| AVG Volume (30 Days) | ★ 2.5M | 194.9K |
| Earning Date | 05-04-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.34% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.81 | N/A |
| Revenue | ★ $9,800,100,000.00 | N/A |
| Revenue This Year | $6.05 | $900.30 |
| Revenue Next Year | $6.51 | $21.97 |
| P/E Ratio | ★ $23.67 | $614.06 |
| Revenue Growth | ★ 13.96 | N/A |
| 52 Week Low | $100.64 | $196.53 |
| 52 Week High | $118.19 | $385.22 |
Technical Indicators
Market Signals| Indicator | WEC | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 64.15 | 60.90 |
| Support Level | $113.34 | $345.04 |
| Resistance Level | $117.35 | $365.60 |
| Average True Range (ATR) | 2.31 | 10.14 |
| MACD | 0.11 | 0.28 |
| Stochastic Oscillator | 65.01 | 84.74 |
Price Performance
Historical ComparisonAbout WEC WEC Energy Group Inc.
WEC Energy Group's electric and gas utility businesses serve electric and gas customers in Illinois, Michigan, Minnesota, and Wisconsin service territories. The company also owns a 60% stake in American Transmission Co. WEC's asset mix is approximately 49% electric generation and distribution, 32% gas distribution, 10% electric transmission, 7% unregulated renewable energy, and 2% LNG distribution and generation.
About ONC BeiGene Ltd. American Depositary Shares
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.